Genprex (GNPX) Receivables (2016 - 2022)

Genprex (GNPX) posted quarterly Receivables of $34852.0 for Q4 2022, little changed quarter-over-quarter from $34852.0 in Q3 2022.

Genprex (GNPX) Receivables (2016 - 2022) Analysis & Trends

Genprex's Receivables history runs 7 years deep, the most recent figure standing at $34852.0 for Q4 2022.

In Q4 2022, Receivables changed N/A year-over-year to $34852.0; the TTM figure through Dec 2022 stood at $34852.0 (changed N/A YoY), while the FY2022 annual figure was $34852.0, changed N/A from the prior year.
Receivables for Q4 2022 stood at $34852.0, roughly flat from $34852.0 in the prior quarter.
The five-year high for Receivables was $34852.0 in Q3 2022, with the low at $85.0 in Q2 2020.
The 5-year median for Receivables is $746.5 (2018), against an average of $9517.2.
The sharpest annual moves came in 2020 and 2022: Receivables sank 99.21% in 2020, then jumped 27342.52% in 2022.
Genprex's Receivables stood at $9297.0 in 2018, then sank by 92.95% to $655.0 in 2019, then sank by 80.61% to $127.0 in 2020, then changed by 0.0% to $127.0 in 2021, then surged by 27342.52% to $34852.0 in 2022.
Business Quant data shows GNPX's Receivables at $34852.0 in Q4 2022, $34852.0 in Q3 2022, and $32171.0 in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	Genprex	1.89 Mn	-13.27 Mn	-	-

Download Data